Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An announcement from PureTech Health ( (GB:PRTC) ) is now available.
PureTech Health announced promising results from its Phase 2b trial of deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF). The trial demonstrated that deupirfenidone significantly slowed lung function decline compared to placebo, with the 825 mg dose showing a robust 80.9% treatment effect. The drug was well-tolerated with fewer gastrointestinal side effects than the current standard-of-care, pirfenidone. These findings support further development and suggest deupirfenidone could become a new standard-of-care for IPF, marking a potential breakthrough in the treatment landscape for this severe lung disease.
More about PureTech Health
PureTech Health plc is a clinical-stage biotherapeutics company focused on developing treatments for debilitating diseases. The company is dedicated to transforming the lives of patients through innovative medical solutions and aims to address significant unmet medical needs in the healthcare sector.
YTD Price Performance: -16.17%
Average Trading Volume: 698,529
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £389.8M
Find detailed analytics on PRTC stock on TipRanks’ Stock Analysis page.
